GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (NAS:SCPH) » Definitions » YoY EPS Growth

scPharmaceuticals (scPharmaceuticals) YoY EPS Growth : -20.00% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is scPharmaceuticals YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. scPharmaceuticals's YoY EPS Growth for the quarter that ended in Mar. 2024 was -20.00%.

scPharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.36.

scPharmaceuticals YoY EPS Growth Historical Data

The historical data trend for scPharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

scPharmaceuticals YoY EPS Growth Chart

scPharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only -11.32 25.99 22.14 -27.45 -9.23

scPharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.14 -2.86 -10.81 -16.67 -20.00

scPharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

scPharmaceuticals's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-1.42--1.3)/ | -1.3 |
=-9.23 %

scPharmaceuticals's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EPS Growth (Q: Mar. 2024 )
=(Earnings per Share (Diluted) (Q: Mar. 2024 )-Earnings per Share (Diluted) (Q: Mar. 2023 )) / | Earnings per Share (Diluted) (Q: Mar. 2023 )) |
=(-0.36--0.3)/ | -0.3 |
=-20.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

scPharmaceuticals YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of scPharmaceuticals's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

scPharmaceuticals (scPharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (NAS:SCPH) » Definitions » YoY EPS Growth
Comparable Companies
ENTA MCRB RENB AEON INZY IVVD GRTS DNTH CBUS PSTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
2SX:Germany
Address
2400 District Avenue, Suite 310, Burlington, MA, USA, 01803
Website
https://www.scpharmaceuticals.com
scPharmaceuticals Inc is a pharmaceutical company. Its pipeline includes products in various stages of clinical and non-clinical development. It focuses on pharmaceutical products in the cardiovascular and infectious disease therapeutic areas. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
Executives
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
5am Partners Iv, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jack A. Khattar director C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
John H Tucker director, officer: President and CEO INDEVUS PHARMACEUTICALS, INC., 99 HAYDEN AVENUE, LEXINGTON MA 02421
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
William Tober Abraham director C/O SCPHARMACEUTICALS INC., 2400 DISTRICT AVENUE, SUITE 310, BURLINGTON MA 01803
Sara Bonstein director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Andrew J. Schwab 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc other: See Remarks 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p. other: See Remarks 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
Orbimed Genesis Gp Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rachael Nokes officer: See Remarks C/O SCPHARMACEUITCALS, INC., 2400 DISTRICT AVENUE, BURLINGTON MA 01803